Both Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) and Pfenex Inc. (NYSEAMERICAN:PFNX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Marinus Pharmaceuticals Inc.||N/A||0.00||43.21M||-0.99||0.00|
Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Marinus Pharmaceuticals Inc. and Pfenex Inc.
Table 2 provides the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Marinus Pharmaceuticals Inc.||0.00%||-83.8%||-74%|
Risk & Volatility
A 3.27 beta means Marinus Pharmaceuticals Inc.’s volatility is 227.00% more than S&P 500’s volatility. From a competition point of view, Pfenex Inc. has a 2.75 beta which is 175.00% more volatile compared to S&P 500.
9.4 and 9.4 are the respective Current Ratio and a Quick Ratio of Marinus Pharmaceuticals Inc. Its rival Pfenex Inc.’s Current and Quick Ratios are 3.6 and 3.6 respectively. Marinus Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Pfenex Inc.
The Ratings and Recommendations for Marinus Pharmaceuticals Inc. and Pfenex Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Marinus Pharmaceuticals Inc.||0||1||4||2.80|
Marinus Pharmaceuticals Inc. has a 305.79% upside potential and an average price target of $15.42.
Institutional & Insider Ownership
Institutional investors owned 72.4% of Marinus Pharmaceuticals Inc. shares and 81.3% of Pfenex Inc. shares. Insiders owned 0.6% of Marinus Pharmaceuticals Inc. shares. Comparatively, 2.14% are Pfenex Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Marinus Pharmaceuticals Inc.||4.36%||15.14%||39.24%||-9.79%||0%||66.9%|
For the past year Marinus Pharmaceuticals Inc.’s stock price has smaller growth than Pfenex Inc.
Pfenex Inc. beats on 6 of the 10 factors Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.